Investigational Drug Information for Iodine-123
✉ Email this page to a colleague
What is the drug development status for Iodine-123?
Iodine-123 is an investigational drug.
There have been 6 clinical trials for Iodine-123.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Heart Failure, Thyroid Diseases, and Coronary Artery Disease. The leading clinical trial sponsors are National Cancer Institute (NCI), Bennett Chin, and GE Healthcare.
Summary for Iodine-123
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 3 (2013-12-01) |
| Vendors | 3 |
Recent Clinical Trials for Iodine-123
| Title | Sponsor | Phase |
|---|---|---|
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | National Cancer Institute (NCI) | Phase 3 |
| Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease | Michele Tagliati, MD | Phase 2 |
| Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology | Nantes University Hospital | Phase 2/Phase 3 |
Clinical Trial Summary for Iodine-123
Top disease conditions for Iodine-123
Top clinical trial sponsors for Iodine-123
US Patents for Iodine-123
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
